Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2903542 | 1.00 | F2R (0.61) | F2RMAPTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL2902532 | 0.83 | L3MBTL1 (0.67) | F2RMAPTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL2905408 | 0.83 | C3AR1 (0.56) | F2RMAPTL3MBTL1KMT2AALDH1A1 | |
| SCHEMBL2902111 | 0.80 | ALDH1A1 (0.69) | MAPTL3MBTL1KMT2AALDH1A1MEN1 | |
| SCHEMBL1399061 | 0.76 | KDM4E (0.44) | F2RMAPTL3MBTL1ALDH1A1ATM | |
| SCHEMBL1399064 | 0.76 | KDM4E (0.44) | F2RMAPTL3MBTL1ALDH1A1ATM | |
| SCHEMBL10300784 | 0.75 | TDP1 (0.57) | ALDH1A1NAMPTGPR183C3AR1LMNA | |
| SCHEMBL2902366 | 0.75 | TDP1 (0.57) | ALDH1A1NAMPTGPR183C3AR1LMNA | |
| SCHEMBL1399036 | 0.75 | F2R (0.44) | F2RMAPTL3MBTL1ALDH1A1GPR183 | |
| SCHEMBL1399035 | 0.75 | F2R (0.44) | F2RMAPTL3MBTL1ALDH1A1GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PEREZ MICHEL (FR) | 2012-09-13 | — | — | US | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | claimed |
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2009-07-09 | — | — | US | claimed |
| EP-2041104-B1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR- I ANTAGONISTS | PF MEDICAMENT (FR) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176803-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | F2R 1/4885MAPT 4777/4885L3MBTL1 2597/4885 |
| US-20120232097-A1 | CINNAMOYL-PIPERAZINE DERIVATIVES AND THEIR USE AS PAR-1 ANTAGONISTS | F2R, F2RL1, F2RL3 | F2R 1/4885MAPT 4777/4885L3MBTL1 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.